Evidence map›Paper›PMID 29204710›Full record

Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2018

Chemotherapy-related neuropathic symptom management: a randomized trial of an automated symptom-monitoring system paired with nurse practitioner follow-up.

Noah Allan Kolb, Albert Gordon Smith, John Robinson Singleton, Susan L Beck, Diantha Howard, Kim Dittus, Summer Karafiath, Kathi Mooney

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 53 citations in OpenAlex.

  1. Efficacy of the PRO-CTCAE mobile application for improving patient participation in symptom management during cancer treatment: a randomized controlled trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Risk factors and interrelationships of taxane-related peripheral neuropathy: a Bayesian network analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Management of neurotoxic reactions induced by antibody-drug conjugates.Asia-Pacific journal of oncology nursing · 2024
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Noah Allan KolbDepartment of Neuroscience, University of Vermont Medical Center, 1 South Prospect Street, MS 405AR2, Burlington, VT, 05401, USA. noah.kolb@uvmhealth.org.ORCID http://orcid.org/0000-0003-2651-2349
Albert Gordon SmithDepartment of Neurology, University of Utah, Salt Lake City, UT, USA.
John Robinson SingletonDepartment of Neurology, University of Utah, Salt Lake City, UT, USA.
Susan L BeckCollege of Nursing, University of Utah, Salt Lake City, UT, USA.
Diantha HowardClinical Research Center, University of Vermont, Burlington, VT, USA.
Kim DittusDepartment of Medicine, Hematology/Oncology, University of Vermont, Burlington, VT, USA.
Summer KarafiathDepartment of Neurology, University of Utah, Salt Lake City, UT, USA.
Kathi MooneyCollege of Nursing, University of Utah, Salt Lake City, UT, USA.
University of Utah · USUniversity of Vermont · USUniversity of Vermont Medical Center · US

Funding

National Institutes of Health KL2TR001065National Institutes of Health R01 CA120558
6 · The paper itself

Abstract

purposeThe purpose of this study was to evaluate a new care model to reduce chemotherapy-induced neuropathic symptoms. Neuropathic symptom usual care was prospectively compared to an automated symptom-monitoring and coaching system, SymptomCare@Home (SCH), which included nurse practitioner follow-up triggered by moderate to severe symptoms.

methodsPatients beginning chemotherapy were randomized to usual care (UC) or to the SCH intervention. This sub-analysis included only taxane/platin therapies. Participants called the automated telephone symptom-monitoring system daily to report numbness and tingling. The monitoring system recorded patient-reported neuropathic symptom severity, distress, and activity interference on a 0-10 scale. UC participants were instructed to call their oncologist for symptom management. SCH participants with symptom severity of ≥ 4 received automated self-care strategies, and a nurse practitioner (NP) provided guideline-based care.

resultsThere were 252 participants, 78.6% of which were female. Mean age was 55.1 years. Mean follow-up was 90.2 ± 39.9 days (81.1 ± 40.3 calls). SCH participants had fewer days of moderate (1.8 ± 4.0 vs. 8.6 ± 17.3, p < 0.001) and severe chemotherapy-induced peripheral neuropathy symptoms (0.3 ± 1.0 vs. 1.1 ± 5.2, p = 0.006). SCH participants had fewer days with moderate and severe symptom-related distress (1.4 ± 3.7 vs. 6.9 ± 15.0, p < 0.001; 0.2 ± 0.9 vs. 1.5 ± 6.1, p = 0.001) and trended towards less activity interference (3.3 ± 1.9 vs. 3.8 ± 2.1, p = 0.08). Other neuropathic symptoms were addressed in 5.8-15.4% of SCH follow-up calls.

conclusionsThe SCH system effectively identified neuropathic symptoms and their severity and, paired with NP follow-up, reduced symptom prevalence, severity, and distress compared to usual care.

Indexed as

Antineoplastic AgentsFemaleFollow-Up StudiesHumansMaleMiddle AgedMonitoring, PhysiologicNurse PractitionersPeripheral Nervous System DiseasesProspective StudiesAntineoplastic AgentsCancerChemotherapyNeuropathic painNeuropathyNurse practitionerSupportive careTelemedicine

Identifiers

PMID29204710
OpenAlexW2772388751

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.